13039-64-0

Basic information

• Product Name: (2S,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol
• Synonyms: (2S,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol
• CAS NO: 13039-64-0
• Molecular Weight: 164.158
• Mol File: 13039-64-0.mol
• Article Data: 83

Chemical Properties

• CAS DataBase Reference: (2S,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol(13039-64-0)
• EPA Substance Registry System: (2S,3R,4R)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3,4-diol(13039-64-0)

Safety Data

• Hazardous Substances Data: 13039-64-0(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 532-20-7 D-lyxose 
• 50-69-1 D-ribose 
• 87-72-9 D-Xylose 
• 5328-37-0 L-arabinose 
• 1114-34-7 D-lyxose 
• 609-06-3 L-xylose 
• 532-20-7 D-xylofuranose 
• 75-36-5 acetyl chloride 
• 58-86-6 D-xylose 
• 36468-53-8 β-D-ribofuranose 
• 63846-98-0 1,2-O-(1-Methylethylidene)-α-D-ribo-pentodialdo-1,4-furanose 
• 4495-04-9 1,2-O-isopropylidene-α-D-allofuranose 
• 2595-05-3 Diacetone D-glucose 

Downstream Products

• 86042-33-3 methyl 2,3,5-tri-O-p-toluyl-D-ribofuranoside 
• 303041-42-1 methyl 2,3,5-tri-O-[3-(trifluoromethyl)benzoyl]-D-ribofuranoside 
• 67689-93-4 methyl 5-O-trityl-α-D-ribofuranoside 
• 59279-39-9 2,5-anhydro-3,4,6-tri-O-(p-nitrobenzoyl)-D-allononitrile 
• 63527-43-5 2,3,5-p-Nitrobenzoyl-D-ribofuranosylbromid 
• 86042-35-5 2,3,5-tri-O-p-toluyl-D-ribofuranosyl bromide 
• 86042-34-4 1-O-acetyl-2,3,5-tri-O-p-toluyl-β-D-ribofuranose 
• 86042-27-5 1-O-acetyl-2,3,5-tri-O-p-nitrobenzoyl-β-D-ribofuranose 
• 86042-26-4 1-O-acetyl-2,3,5-tri-O-p-nitrobenzoyl-α-D-ribofuranose 
• 86042-36-6 2,5-anhydro-3,4,6-tri-O-p-toluoyl-D-allononitrile 
• 65-46-3 CYTIDINE 
• 37077-80-8 2,3,5-tri-O-acetyl-1-O-methyl-β-D-ribofuranose 
• 22860-91-9 2,3,5-tri-O-benzoyl-D-ribofuranosyl bromide 
• 303041-45-4 2',3',5'-tri-O-[3-(trifluoromethyl)benzoyl]-5-methyluridine 

Relevant articles and documents

MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF

The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard nucleoside. An oligomeric compound comprising a modified oligonucleotide consisting of 12-30 linked nucleosides, wherein at least one nucleoside of the modified oligonucleotide is a stereo-non-standard nucleoside; and wherein the oligomeric compound is selected from among an RNAi compound, a modified CRISPR compound, and an artificial mRNA compound.

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Glycosides and Glycoconjugates of the Diterpenoid Isosteviol with a 1,2,3-Triazolyl Moiety: Synthesis and Cytotoxicity Evaluation

Several glycoconjugates of the diterpenoid isosteviol (16-oxo-ent-beyeran-19-oic acid) with a 1,2,3-triazolyl moiety were synthesized, and their cytotoxicity was evaluated against some human cancer and normal cell lines. Most of the synthesized compounds demonstrated weak inhibitory activities against the M-HeLa and MCF-7 human cancer cell lines. Three lead compounds, 54, 56 and 57, exhibited high selective cytotoxic activity against M-HeLa cells (IC50 = 1.7-1.9 μM) that corresponded to the activity of the anticancer drug doxorubicin (IC50 = 3.0 μM). Moreover, the lead compounds were not cytotoxic with respect to a Chang liver human normal cell line (IC50 > 100 μM), whereas doxorubicin was cytotoxic to this cell line (IC50 = 3.0 μM). It was found that cytotoxic activity of the lead compounds is due to induction of apoptosis proceeding along the mitochondrial pathway. The present findings suggest that 1,2,3-triazolyl-ring-containing glycoconjugates of isosteviol are a promising scaffold for the design of novel anticancer agents.